Our data support a potential role for GLP-1 receptor agonists as a means to target these adipose-dependent pathways in the prevention of multiple myeloma, adding to previous studies reporting improved survival in myeloma patients taking metformin.37 This evidence concerns the gene GLP1R and AL amyloidosis.